John Hood has found another misfit drug to love — and bring back from the dead
Taladegib, an inhibitor of the chronic Hedgehog signaling pathway, died a slow and remorseless death.
Eli Lilly licensed it out to Jonathan Lim’s Ignyta in 2015, which later retreated from the troubled basal cell carcinoma program. And then it was passed along with more valuable assets to Roche in the $1.7 billion Ignyta buyout, where it languished further.
John Hood actually found out before Eli Lilly that the drug was being kicked back by Roche, which already had a rival with Erivedge (vismodegib). And when Lilly execs pointed him to the Basel multinational when he inquired about it, he advised them to wait a few days. And then he went back and got it for himself.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,500+ biopharma pros reading Endpoints daily — and it's free.